In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Thulien, Kyle J ^a   Belch, Andrew R ^a   Reiman, Tony ^a   Pilarski, Linda M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Autologous transplant; Cancer stem cell; Clinical correlates; Clonotypic signature; Multiple myeloma; Quantitative analysis; Tumor burden

Indexed keywords

ARTICLE; ASPIRATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CELL; CANCER RECURRENCE; EVENT FREE SURVIVAL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; REAL TIME POLYMERASE CHAIN REACTION; VDJ EXON;

AGED; AGED, 80 AND OVER; CLONE CELLS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; INDUCTION CHEMOTHERAPY; MULTIPLE MYELOMA; PROGNOSIS; V(D)J RECOMBINATION;

EID: 84867624040     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-78     Document Type: Article

References (45)

1. Pilarski LM, Hipperson G, Seeberger K, et al. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000, 95:1056-1065.
2. Pilarski LM, Baigorri E, Mant MJ, et al. Multiple myeloma includes CD20+ B and plasma cells that persist in patients treated with rituximab. Clinical Medicine: Oncology 2008, 2:275-285.
3. Reiman T, Seeberger K, Taylor BJ, et al. Persistent pre-switch myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone. Blood 2001, 98:2791-2799. 10.1182/blood.V98.9.2791, 11675353.
4. Kirshner J, Thulien K, Martin LD, et al. A unique 3-D model for evaluating the impact of therapy on multiple myeloma. Blood 2008, 112:2935-2945. 10.1182/blood-2008-02-142430, 18535198.
5. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004, 103:2332-2336. 10.1182/blood-2003-09-3064, 3311914, 14630803.
6. Debes Marun CS, Belch AR, Pilarski LM. In multiple myeloma, bone-marrow lymphocytes harboring the same chromosomal abnormalities as autologous plasma cells predict poor survival. Am J Hematol 2012, 87:579-587. 10.1002/ajh.23194, 3433796, 22495885.
7. Jakubikova J, Adamia S, Kost-Alimova M, et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 2011, 117:4409-4419. 10.1182/blood-2010-02-267344, 3099565, 21321360.
8. Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011, 117:4701-4705. 10.1182/blood-2010-10-299529, 21292778.
9. Paul E, Sutlu T, Deneberg S, et al. Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation. Oncol Rep 2009, 22:137-142.
10. Hwang IH, Chung JS, Shin HJ, et al. Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation. Korean J Intern Med 2011, 26:76-81. 10.3904/kjim.2011.26.1.76, 3056259, 21437166.
11. Harousseau JL, Attal M, Vet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009, 114:3139-3146. 10.1182/blood-2009-03-201053, 19638622.
12. Paiva B, Vidriales MB, Perez JJ, et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica 2009, 94:1599-1602. 10.3324/haematol.2009.009100, 2770972, 19880781.
13. Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011, 117:4696-4700. 10.1182/blood-2010-10-300970, 3293763, 21292777.
14. Kapoor P, Rajkumar SV. Update on risk stratification and treatment of newly diagnosed multiple myeloma. Int J Hematol 2011, 94:310-320. 10.1007/s12185-011-0947-z, 22005834.
15. Szczepek AJ, Seeberger K, Wizniak J, et al. A high frequency of circulating B cells share clonotypic IgH VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single cell and in situ RT-PCR. Blood 1998, 92:2844-2855.
16. Paiva B, Gutierrez NC, Rosinol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012, 119:687-691. 10.1182/blood-2011-07-370460, 22128143.
17. Peceliunas V, Janiulioniene A, Matuzeviciene R, Zvirblis T, Griskevicius L. Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma. Leuk Lymphoma 2012, 53:641-643. 10.3109/10428194.2011.627481, 21955292.
18. Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008, 112:4017-4023. 10.1182/blood-2008-05-159624, 2581991, 18669875.
19. Mateo G, Montalban MA, Vidriales MB, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008, 26:2737-2744. 10.1200/JCO.2007.15.4120, 18443352.
20. Cremer FW, Ehrbrecht E, Kiel K, et al. Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma. Bone Marrow Transplant 2000, 26:851-858. 10.1038/sj.bmt.1702628, 11081384.
21. Corradini P, Cavo M, Lokhorst H, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003, 102:1927-1929. 10.1182/blood-2003-01-0189, 12738666.
22. Lipinski E, Cremer FW, Ho AD, Goldschmidt H, Moos M. Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2001, 28:957-962. 10.1038/sj.bmt.1703276, 11753551.
23. Bakkus MH, Bouko Y, Samson D, et al. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol 2004, 126:665-674. 10.1111/j.1365-2141.2004.05120.x, 15327517.
24. Raab MS, Cremer FW, Breitkreutz IN, et al. Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Ann Oncol 2005, 16:611-617. 10.1093/annonc/mdi123, 15737985.
25. Fenk R, Ak M, Kobbe G, et al. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma. Haematologica 2004, 89:557-566.
26. Laubach JP, Mitsiades CS, Mahindra A, et al. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw 2009, 7:947-960.
27. Kapoor P, Kumar S, Fonseca R, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009, 114:518-521. 10.1182/blood-2009-01-202010, 2713462, 19324902.
28. Kumar SK, Uno H, Jacobus SJ, et al. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2011, 118:4359-4362. 10.1182/blood-2011-03-342089, 3204907, 21860025.
29. Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000, 18:2273-2281.
30. Martinez-Sanchez P, Montejano L, Sarasquete ME, et al. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response. Br J Haematol 2008, 142:766-774. 10.1111/j.1365-2141.2008.07263.x, 18637804.
31. Kroger N, Badbaran A, Lioznov M, et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol 2009, 37:791-798. 10.1016/j.exphem.2009.03.008, 19487069.
32. Galimberti S, Benedetti E, Morabito F, et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res 2005, 29:961-966. 10.1016/j.leukres.2005.01.017, 15978948.
33. Rimelen V, Ferrand C, Debecker A, et al. Relative quantification of residual tumor cells by lightcycler real-time IgH PCR in autografted multiple myeloma patients. Leukemia 2005, 19:492-495. 10.1038/sj.leu.2403620, 15625553.
34. Greipp PR, San MJ, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005, 23:3412-3420. 10.1200/JCO.2005.04.242, 15809451.
35. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 2003, 122:441-450. 10.1046/j.1365-2141.2003.04456.x, 12877671.
36. Fassas AB, Tricot G. Chromosome 13 deletion/hypodiploidy and prognosis in multiple myeloma patients. Leuk Lymphoma 2004, 45:1083-91. 10.1080/10428190310001642710, 15359986.
37. Zojer N, Konigsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000, 95:1925-1930.
38. Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003, 101:1520-1529. 10.1182/blood-2002-06-1675, 12393535.
39. Sarasquete ME, Garcia-Sanz R, Gonzalez D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005, 90:1365-1372.
40. Taylor BJ, Kriangkum J, Strachan ER, Wizniak J, Pilarski LM. Identification of clonotypic IgH VDJ sequences in multiple myeloma. Methods Mol Med 2005, 113:121-144.
41. Debes-Marun CS, Dewald GW, Bryant S, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003, 17:427-36. 10.1038/sj.leu.2402797, 12592343.
42. Cremer FW, Kartal M, Hose D, et al. High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH. Cancer Genet Cytogenet 2005, 161:116-124. 10.1016/j.cancergencyto.2005.02.015, 16102581.
43. Lopez-Corral L, Gutierrez NC, Vidriales MB, et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res 2011, 17:1692-1700. 10.1158/1078-0432.CCR-10-1066, 21325290.
44. Drach J, Schuster J, Nowotny H, et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 1995, 55:3854-3859.
45. Alfaro R, Rosell J, Duran MA, et al. Structural rearrangements of trisomies are a risk marker of clinical progression in hyperdiploid multiple myeloma. Anticancer Res 2011, 31:1599-1602.